Frank A. Laws, M.D., and Richard W. Smalling, M.D., Ph.D.

Dr. Laws is a Fellow in the Department of Internal Medicine, Division of Cardiology, University of Texas-Houston Medical School.

Dr. Laws reports no commercial conflict of interest. Dr. Smalling has received grant/research support from Centocor/Boston Scientific within the last three years.

This activity is made possible by an unrestricted educational grant from the Novartis Foundation for Gerontology.

Release Date: 01/03/2000
Termination Date: 01/03/2003

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Upon completion of this Cyberounds^®, the participant should be able to:

• Identify why blockade of the renin-angiotensin aldosterone system (RAAS) confers a beneficial effect in patients with congestive heart failure
• Identify pathways involved in the production of angiotensin-II and receptors that mediate the effects of angiotensin-II
• List the objectives of ongoing clinical trials assessing the role of ARBs in the treatment of patients with congestive heart failure.

 

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms of this CME activity